Ace Report Cover
THR: Celecoxib more effective than ibuprofen in prevention of heterotopic bone formation
Reprints
Cite This
Reprints
Cite This
AceReport Image
Arthroplasty
THR: Celecoxib more effective than ibuprofen in prevention of heterotopic bone formation
J Bone Joint Surg Br. 2007 Feb;89(2):155-9.

250 patients with severe hip osteoarthritis were randomized to either receive ibuprofen or celecoxib to determine the relative benefits of these drugs in preventing heterotopic ossification following total hip replacement (THR). The results at 3 months post-op indicated that a ten day trial of celecoxib during the post-op period reduced the risk of heterotopic ossification.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with


OR
Forgot Password?

OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. THR: Celecoxib more effective than ibuprofen in prevention of heterotopic bone formation. ACE Report. 2013;3(8):30. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report